STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIP
  4. [Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president and chief HR officer Krista Davis reported two stock transactions involving company common shares. On February 26, 2026, she acquired 10,810 shares through a restricted stock award at $77.15 per share, bringing her direct holdings to 60,073 shares. This award is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares were withheld at $73.90 per share to cover tax obligations related to the vesting of a prior restricted stock grant, leaving her with 58,518 directly owned shares. The tax withholding is characterized as a payment of tax liability by delivering securities, not an open-market sale.

Positive

  • None.

Negative

  • None.

Insights

Routine stock award and tax withholding, net increase in reported holdings.

The transactions show Krista Davis receiving a restricted stock award of 10,810 shares on February 26, 2026, followed by withholding of 1,555 shares on February 28, 2026 to satisfy taxes on a prior vesting event. Both are standard equity compensation mechanics.

The award vests in four equal annual installments starting on the first anniversary of February 26, 2026, indicating a multi-year retention structure. After these transactions, her directly owned common stock stands at 58,518 shares, based on the most recent figure disclosed.

Because these are non-market, compensation-related entries, with the tax withholding exempt under Rule 16(b)-3, they primarily update long-term incentive alignment rather than signaling discretionary buying or selling activity.

Insider Davis Krista
Role SVP, CHIEF HR OFFICER
Type Security Shares Price Value
Tax Withholding Common Stock 1,555 $73.90 $115K
Grant/Award Common Stock 10,810 $77.15 $834K
Holdings After Transaction: Common Stock — 58,518 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis Krista
(Last) (First) (Middle)
C/O ANI PHARMACEUTICALS, INC.
210 MAIN STREET WEST
(Street)
BAUDETTE MN 56623
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF HR OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 A(1) 10,810 A $77.15 60,073 D
Common Stock 02/28/2026 F(2) 1,555 D $73.9 58,518 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.
Remarks:
/s/ Krista Davis, by attorney-in-fact Meredith W. Cook 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Krista Davis report for ANI Pharmaceuticals (ANIP)?

Krista Davis reported a restricted stock award of 10,810 ANI Pharmaceuticals shares and a separate withholding of 1,555 shares for taxes. These transactions updated her direct ownership and reflect routine equity compensation and related tax settlement activity, rather than open-market buying or selling.

How many ANI Pharmaceuticals shares did Krista Davis acquire in the latest Form 4?

She acquired 10,810 shares of ANI Pharmaceuticals common stock through a restricted stock award at $77.15 per share. This grant increased her direct holdings to 60,073 shares immediately after the award, before subsequent tax-withholding transactions reduced the reported balance.

Why were 1,555 ANI Pharmaceuticals (ANIP) shares disposed of in Krista Davis’s Form 4?

The 1,555 ANI Pharmaceuticals shares were withheld to cover taxes related to the vesting of 3,040 previously granted restricted shares. This disposition is classified as a tax-withholding transaction, exempt under Rule 16(b)-3, and not as an open-market sale of stock.

What is the vesting schedule of Krista Davis’s new restricted stock award at ANI Pharmaceuticals?

The restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. This structure spreads the award’s benefits over several years, supporting ongoing retention and long-term alignment with ANI Pharmaceuticals’ performance.

How many ANI Pharmaceuticals shares does Krista Davis own after these insider transactions?

After the reported award and tax-withholding disposition, Krista Davis directly owns 58,518 shares of ANI Pharmaceuticals common stock. This is the most recent total provided and reflects the balance as of the transaction dated February 28, 2026, following the tax-related share withholding.

Are Krista Davis’s recent ANI Pharmaceuticals stock transactions open-market trades?

No, both transactions are compensation-related. One is a restricted stock award grant, and the other is a tax-withholding disposition tied to vesting of earlier restricted stock. Neither entry represents a discretionary open-market purchase or sale of ANI Pharmaceuticals shares.